Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Meta-analysis fine-mapping is often miscalibrated at single-variant resolution

View ORCID ProfileMasahiro Kanai, Roy Elzur, Wei Zhou, Global Biobank Meta-analysis Initiative, Mark J Daly, Hilary K Finucane
doi: https://doi.org/10.1101/2022.03.16.22272457
Masahiro Kanai
1Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
2Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
3Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
4Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA
5Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Masahiro Kanai
  • For correspondence: mkanai@broadinstitute.org finucane@broadinstitute.org
Roy Elzur
1Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
2Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
3Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Zhou
1Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
2Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
3Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J Daly
1Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
2Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
3Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
6Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hilary K Finucane
1Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
2Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
3Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mkanai@broadinstitute.org finucane@broadinstitute.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Meta-analysis is pervasively used to combine multiple genome-wide association studies (GWAS) into a more powerful whole. To resolve causal variants, meta-analysis studies typically apply summary statistics-based fine-mapping methods as they are applied to single-cohort studies. However, it is unclear whether heterogeneous characteristics of each cohort (e.g., ancestry, sample size, phenotyping, genotyping, or imputation) affect fine-mapping calibration and recall. Here, we first demonstrate that meta-analysis fine-mapping is substantially miscalibrated in simulations when different genotyping arrays or imputation panels are included. To mitigate these issues, we propose a summary statistics-based QC method, SLALOM, that identifies suspicious loci for meta-analysis fine-mapping by detecting outliers in association statistics based on ancestry-matched local LD structure. Having validated SLALOM performance in simulations and the GWAS Catalog, we applied it to 14 disease endpoints from the Global Biobank Meta-analysis Initiative and found that 68% of loci showed suspicious patterns that call into question fine-mapping accuracy. These predicted suspicious loci were significantly depleted for having likely causal variants, such as nonsynonymous variants, as a lead variant (2.8x; Fisher’s exact P = 6.2 × 10−4). Compared to fine-mapping results in individual biobanks, we found limited evidence of fine-mapping improvement in the GBMI meta-analyses. Although a full solution requires complete synchronization across cohorts, our approach identifies likely spurious results in meta-analysis fine-mapping. We urge extreme caution when interpreting fine-mapping results from meta-analysis.

Competing Interest Statement

M.J.D. is a founder of Maze Therapeutics. All other authors declare no competing interests.

Funding Statement

M.K. was supported by a Nakajima Foundation Fellowship and the Masason Foundation. H.K.F. was funded by NIH grant DP5 OD024582.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study involves only openly available GWAS summary statistics, which can be obtained from: * the Global Biobank Meta-analysis Initiative, https://www.globalbiobankmeta.org/resources * the GWAS Catalog, https://www.ebi.ac.uk/gwas/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The GBMI summary statistics for the 14 endpoints are available at https://www.globalbiobankmeta.org/resources and are browserble at the GBMI PheWeb website (http://results.globalbiobankmeta.org/).

https://www.globalbiobankmeta.org/resources

http://results.globalbiobankmeta.org/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted March 20, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Meta-analysis fine-mapping is often miscalibrated at single-variant resolution
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Meta-analysis fine-mapping is often miscalibrated at single-variant resolution
Masahiro Kanai, Roy Elzur, Wei Zhou, Global Biobank Meta-analysis Initiative, Mark J Daly, Hilary K Finucane
medRxiv 2022.03.16.22272457; doi: https://doi.org/10.1101/2022.03.16.22272457
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Meta-analysis fine-mapping is often miscalibrated at single-variant resolution
Masahiro Kanai, Roy Elzur, Wei Zhou, Global Biobank Meta-analysis Initiative, Mark J Daly, Hilary K Finucane
medRxiv 2022.03.16.22272457; doi: https://doi.org/10.1101/2022.03.16.22272457

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (860)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (250)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8562)
  • Forensic Medicine (4)
  • Gastroenterology (384)
  • Genetic and Genomic Medicine (1753)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1244)
  • Health Policy (621)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (374)
  • Infectious Diseases (except HIV/AIDS) (10303)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (212)
  • Neurology (1678)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (451)
  • Oncology (929)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (536)
  • Pharmacology and Therapeutics (253)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1770)
  • Public and Global Health (3841)
  • Radiology and Imaging (624)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)